For the Inventor, By the Inventor

Enter assignee name

Frankfurt, Germany

Zentaris Ag

Calculating rank

USPTO Granted Patents = 20

% Expired Patents = 40.0

CIPO Patents = 1

Forward Citations = 200

Loading Chart...

Loading Chart...

68 inventors (with patents filed for the assignee):

Bernd Nickel (7 out of 27 patents)

Thomas Beckers (4 out of 36 patents)

Bernhard Kutscher (4 out of 45 patents)

4. Peter Emig (4 out of 29 patents)

5. Thomas Klenner (4 out of 11 patents)

6. Jürgen Engel (4 out of 15 patents)

7. Thomas Reissmann (3 out of 16 patents)

8. Eckhard Günther (3 out of 4 patents)

9. Peter Hilgard (3 out of 17 patents)

10. Siavosh Mahboobi (2 out of 5 patents)

11. Herwig Pongratz (2 out of 5 patents)

12. Norbert Schmees (2 out of 31 patents)

13. Eckhard Guenther (2 out of 16 patents)

14. Emmanuel Polymeropoulos (2 out of 24 patents)

15. Holger Hess-Stumpp (2 out of 13 patents)

20 patents: Sort by Forward Citations

1. 7378522 - Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone (2008-05-27),

2. 7122570 - Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) (2006-10-17),

3. 6890926 - Heteroaryl derivatives and their use as medicaments (2005-05-10),

4. 6863891 - Oligopeptide lyophilisate, their preparation and use (2005-03-08),

5. 6861409 - Growth hormone secretagogues (2005-03-01),

6. 6849715 - Agents useful for inactivation of Ras subfamily proteins (2005-02-01),

7. 6812243 - Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation (2004-11-02),

8. 6790858 - Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone (2004-09-14),

9. 6727252 - Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds (2004-04-27),

10. 6716817 - Method of treatment of female infertility (2004-04-06),

11. 6706722 - Heteroaryl derivatives and their use as medicaments (2004-03-16),

12. 6696428 - Use of dopamine receptor antagonists in palliative tumor therapy (2004-02-24),

13. 6638935 - Heteroary1 derivatives and their use as medicaments (2003-10-28),

14. 6627609 - LHRH antagonists having improved solubility properties (2003-09-30),

15. 6576624 - Use of dopamine receptor antagonists in palliative tumor therapy (2003-06-10),

Company Overview

Zentaris AG is a biopharmaceutical company based in Frankfurt, Germany, specializing in the development of innovative therapeutics for the treatment of various diseases. The company focuses on advancing its proprietary drug candidates through clinical development, particularly in the fields of oncology and endocrinology. Zentaris is committed to addressing unmet medical needs by leveraging its expertise in drug discovery and development, aiming to bring novel solutions to patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

20 Patents

#44 in Frankfurt

#2,223 in Germany

#31,380 in the World

Frankfurt, Germany

Zentaris Ag

Forward Citations = 200

68 inventors:

Bernd Nickel (7 out of 27 patents)

Thomas Beckers (4 out of 36 patents)

Bernhard Kutscher (4 out of 45 patents)

4. Peter Emig (4 out of 29 patents)

5. Thomas Klenner (4 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zentaris Ag. Retrieved from https://idiyas.com/company/zentaris-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…